Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IDP-124 Lotion
IDP-124 · 2 trials · 1 indication
Investigator Global Assessment (IGA) was determined based on evaluator-blinded evaluations of the inflammatory signs of atopic dermatitis. Evaluations were scored using a 5-point scale from clear (0) to severe (4), with higher numbers indicating worse scores.
| Arm | Type | Description |
|---|---|---|
| IDP-124 Lotion | EXPERIMENTAL | IDP-124 Lotion, twice-daily application |
| IDP-124 Vehicle Lotion | ACTIVE_COMPARATOR | IDP-124 Vehicle Lotion, twice-daily application |
| Name | Type | Description |
|---|---|---|
| IDP-124 Lotion | DRUG | IDP-124 Lotion, twice-daily application |
| IDP-124 Vehicle Lotion | DRUG | IDP-124 Vehicle Lotion, twice-daily application |
Inclusion Criteria: * Male or female at least 2 years of age and older * Written and verbal informed consent must be obtained; subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent durin...
Top 20 of 26 competitors
IDP-124 is an investigational small molecule being studied for the treatment of moderate to severe atopic dermatitis. It is formulated as a lotion and is being developed for use in both pediatric and adult patients, with clinical trials enrolling subjects aged 2 years and older.
IDP-124 is being developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is the sponsor behind the clinical development program for this investigational dermatology asset.
IDP-124 is in Phase 3 clinical development. It has not been approved by the FDA and remains an investigational therapy. Two Phase 3 trials have been completed, and no trials are currently active.
IDP-124 has been evaluated in two completed Phase 3 trials: NCT03058783, which enrolled 328 subjects, and NCT03002571, which enrolled 338 subjects. Both studied the lotion in moderate to severe atopic dermatitis across pediatric and adult patients in the United States.
Yes, IDP-124 Lotion is an alternative name for IDP-124. Both names refer to the same investigational small molecule developed by Bausch Health Companies Inc. for moderate to severe atopic dermatitis.
Both Phase 3 trials of IDP-124 were randomized, double-blind, and active-controlled studies. They enrolled a combined total of 666 subjects with moderate to severe atopic dermatitis, including pediatric and adult participants aged 2 years and older, and both trials have been completed.